MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 4 5 Next >
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in March Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
From Natera, Inc.
Via Business Wire
Tickers NTRA
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Study Validates Signatera™ in Endometrial Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
From Natera, Inc.
Via Business Wire
Tickers NTRA
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Acquires Reproductive Health Assets from Invitae
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
Tickers NTRA
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Third Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in November Investor Conferences
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
From Natera, Inc.
Via Business Wire
Tickers NTRA
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Third Quarter 2023 Results on November 8
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
From Natera, Inc.
Via Business Wire
Tickers NTRA
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
From Natera, Inc.
Via Business Wire
Tickers NTRA
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story